0001209191-23-027051.txt : 20230503 0001209191-23-027051.hdr.sgml : 20230503 20230503170158 ACCESSION NUMBER: 0001209191-23-027051 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230501 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MCKENZIE DIANA CENTRAL INDEX KEY: 0001754648 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 23885190 MAIL ADDRESS: STREET 1: METLIFE STREET 2: 200 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10166 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-01 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001754648 MCKENZIE DIANA C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 0 Common Stock 2023-05-01 4 D 0 1449 D 1435 D Common Stock 2023-05-01 4 A 0 1168 0.00 A 2603 D Common Stock 207 I Held in Trust Deferred Stock Units 2023-05-01 4 A 0 1449 A Common Stock 1449 4566.521 D Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2022, Ms. McKenzie deferred the receipt of 1,449 shares of common stock and received instead 1,449 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,449 shares of common stock in exchange for an equal number of deferred stock units. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death. /s/ Christiana Stevenson, Attorney-in-Fact 2023-05-03